anticoagulants, pentasacharide analogues, fondaparinux 2.5 mg/d for 45 days
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2010 Sep 23;363(13):1222-32 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, superficial venous thrombosis, legs The Use of
anticoagulants, pentasacharide analogues, fondaparinux 2.5 mg/d for 45 days
As Treatment, Acute
Is better Than
placebo
To reduce pulmonary embolism or deep-vein thrombosis (1.3% placebo VS 0.2% fondap) and a combined endpoint of thromboembolic events (6% placebo VS 1% fondap).